Water Tower Research Spotlights Ainos' Advances and Milestones in Digital Olfaction and Healthcare: Entering Inflection Point in 2H25

Ainos Hits Inflection Point with AI Nose Pilot Ramp in Senior Care, Robotics, and Semiconductors

Key VELDONA® Human Clinical Studies Secure Taiwan Regulatory Greenlight, Accelerating Development

SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' critical milestones and strategic advancements in 1H25, and its robust roadmap for the remainder of the year, with multiple large scale AI Nose pilot programs and Veldonaclinical trials on deck.

Key Highlights from the Report:

• Breakthroughs in accuracy and revenues demonstrate senior care market readiness: AI Nose achieved an 85% accuracy rate in hygiene monitoring, exceeding a performance target of 80%. Ainos recorded AI Nose revenues for the first time in 1Q25, driven by sales for the elderly care program in Japan. Expanded pilot initiatives in Japan are in motion, with exploratory efforts underway in Taiwan.

• SmellTech robotics integration moving quickly, next step real-world testing: Ainos and robotics partner ugo completed the first installation of AI Nose on ugo's service robots, and quickly completed the software integration of a full backend control system. Field testing with live data collection is scheduled for 2H25, targeting public infrastructure environments in Japan such as utilities, airports, and maintenance settings.

• Smart factory innovation accelerates through deepened collaboration with a major semiconductor company: Ainos and ASE have identified more than 30 use cases for AI Nose across predictive maintenance, environmental safety, and process optimization. The partnership was recently extended to ASE's Chung Li facility in Taiwan, with the potential to expand to other ASE sites. Ainos expects to begin pilot programs at select sites among ASE's smart factories worldwide during 2H25.

• Smell ID database expansion lays strong foundation for scalable, AI-powered olfactory analytics: AI Nose's preliminary validation trials showed over 90% accuracy in identifying real-world smells, including meat, food, and drinks, supporting Ainos' plans to expand the Smell ID library.

• Veldona demonstrates clinical advancements in both human and veterinary studies:

Ainos has secured regulatory clearance in Taiwan to initiate human trials of Veldonatargeting HIV-related warts and primary Sjogren's syndrome, with patient enrollment expected in 2H25 and study completion projected for 2H26 and 1H27, respectively.In parallel, early results of ongoing Feline Chronic Gingivostomatitis (FCGS) study have shown 10%-44% symptom improvements, accompanied by a reduction in steroid usage and no reported adverse effects. Final data are expected in mid-2026.